Next-Generation Antibodies Market To Be Worth $11.6bn In 2020, A New Visiongain Study Predicts

07 September 2018
Pharma

A new report by visiongain, published in April 2016, forecasts that the worldwide next-generation antibodies market will generate $11.6 billion in 2020. That revenue forecast and others appear in Next-Generation Antibody Therapies Market Forecast 2016-2026: Explore Developments and Sales Potentials for ADCs, Engineered Antibodies, ALPs, Bispecific and Biosimilar Agents.

Visiongain is a business information publisher and consultancy based in London, UK. Its purpose is to help companies and other organisations assess the potentials of industries and market in healthcare and other fields.

Arshad Ahad, a senior pharmaceutical industry analyst in visiongain, said:
“Next-generation antibody therapies are treatments based on antibodies that have been engineered or otherwise designed to have advantages over simple monoclonal antibodies. Next-generation antibodies are establishing themselves in the market, seven years after the current crop of novel therapies first reached the market with the approval of Kalbitor and Removab in 2009.

“Sales of Adcetris and Kadcyla constitute the majority of revenues in the market in 2016, but over the next ten years rapid growth will stem from the launch of biosimilar drugs, and later from new engineered and bispecific antibody therapies. A strong and varied R&D pipeline will propel this market to new heights from 2016 to 2026.”

First visiongain’s new study provides revenue forecasts to 2026 for five submarkets and the overarching world market:

• Antibody-drug conjugates
• Engineered antibodies
• Bispecific antibodies
• Antibody fragments and ALPs
• Biosimilar antibodies.

In addition that investigation shows revenue forecasts to 2026 for seven drugs:

• Adcetris
• Kadcyla
• Gazyva/Gazyvaro
• Poteligeo
• Removab
• Blincyto
• Kalbitor.

That analysis also shows revenue forecasts to 2026 for four regional markets:

• US
• EU5 group
• Asia-Pacific region
• Latin America
• Rest of the world.

The new report discusses forces stimulating sales growth over the next ten years, as well as forces restraining that industry and market. That work also shows interviews with three companies – Ablynx, arGEN-X and Mersana Therapeutics.

Next-Generation Antibody Therapies Market Forecast 2016-2026 adds to visiongain’s reports on industries and markets in healthcare. Together those studies cover pharmaceuticals, biotechnology, outsourced services, diagnostics and medical devices.

Recent News

Visiongain Publishes European Antibiotics Market Report 2021-2031

Penicillin segment holds majority of the market share owing to maximum prescription as well as the most generic manufacturers throughout the industry.

22 June 2021

Read

Visiongain Publishes Companion Diagnostics (CDx) Market Report 2021-2031

Over the last few years, companion diagnostics has gained widespread attention due to the technological advancements, growing demand for precision medicine, and accelerating demand for targeted therapy.

17 June 2021

Read

Visiongain Publishes Cellular Immunotherapy Market Report 2021-2031

Increasing prevalence of cancers and rising demand for advanced therapies for cancer treatment are the major factors driving the demand for cellular immunotherapies.

15 June 2021

Read

Visiongain Publishes Gene Therapy R&D Market Report 2021-2031

Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions.

14 June 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever